{"id":68716,"date":"2026-06-22T22:12:30","date_gmt":"2026-06-22T14:12:30","guid":{"rendered":"https:\/\/flcube.com\/?p=68716"},"modified":"2026-06-22T22:12:32","modified_gmt":"2026-06-22T14:12:32","slug":"antengene-corporation-secures-980m-global-licensing-deal-with-k2-therapeutics-for-cdh6xcd3-bispecific-t-cell-engager","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68716","title":{"rendered":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Antengene Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6996:HKG\">HKG: 6996<\/a>) announced a strategic <strong>global licensing agreement<\/strong> with <strong>US-based K2 Therapeutics<\/strong> for <strong>ATG-106<\/strong>, its <strong>first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE)<\/strong> in preclinical development for solid tumors. The deal includes an additional <strong>option agreement<\/strong> for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding <strong>US$980 million<\/strong> and global rights excluding Greater China.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-financial-terms\" class=\"wp-block-heading\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Asset<\/strong><\/td><td>ATG-106 (CDH6\u00d7CD3 bispecific TCE)<\/td><\/tr><tr><td><strong>Additional Asset<\/strong><\/td><td>Undisclosed preclinical bispecific TCE (option agreement)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global, excluding Greater China<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>~US$20 million (cash + minority equity in K2 asset company)<\/td><\/tr><tr><td><strong>ATG-106 Milestones<\/strong><\/td><td>Up to US$960.5 million (development, regulatory, sales)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Antengene&#8217;s proprietary AnTenGager platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-innovation-amp-competitive-differentiation\" class=\"wp-block-heading\">Technology Innovation &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AnTenGager Platform:<\/strong> Proprietary TCE approach featuring <strong>sterically shielded CD3-binding arm<\/strong> that activates only upon target antigen binding<\/li>\n\n\n\n<li><strong>Enhanced Safety Profile:<\/strong> Steric shielding mechanism reduces off-tumor toxicity and cytokine release syndrome (CRS) risk compared to conventional TCEs<\/li>\n\n\n\n<li><strong>Potent Anti-Tumor Activity:<\/strong> Maintains robust T-cell redirection efficacy while improving tolerability profile<\/li>\n\n\n\n<li><strong>CDH6 Target Rationale:<\/strong> CDH6 (Cadherin-6) is overexpressed in multiple solid tumors including renal cell carcinoma, ovarian cancer, and lung adenocarcinoma, with limited expression in healthy tissues<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-context\" class=\"wp-block-heading\">Strategic Implications &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Validation:<\/strong> US partnership validates Antengene&#8217;s innovative TCE platform and provides non-dilutive funding for continued pipeline development<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Equity component in K2&#8217;s asset company provides potential upside participation beyond traditional royalty structures<\/li>\n\n\n\n<li><strong>Pipeline De-Risking:<\/strong> Option agreement for second undisclosed candidate demonstrates K2&#8217;s confidence in Antengene&#8217;s broader TCE capabilities<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Positions Antengene among leading Chinese biotech companies successfully out-licensing novel immuno-oncology assets to Western partners<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-impact-amp-development-strategy\" class=\"wp-block-heading\">Financial Impact &amp; Development Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>~$20 million near-term consideration<\/strong> provides immediate funding to advance Antengene&#8217;s internal pipeline while the substantial milestone structure aligns incentives for successful global development. The exclusion of Greater China rights allows Antengene to retain commercial opportunities in its home market while leveraging K2&#8217;s global development expertise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts note that the deal represents one of the largest preclinical-stage out-licensing agreements from a Chinese biotech company in 2026, reflecting growing international recognition of China&#8217;s innovative drug discovery capabilities. The AnTenGager platform&#8217;s differentiated safety approach addresses a critical limitation that has hindered broader adoption of T-cell engaging therapies in solid tumors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, milestone payments, and development timelines. Actual results may differ due to clinical trial outcomes, regulatory decisions, and partner performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200190_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026062200190_c (1).\"><\/object><a id=\"wp-block-file--media-33b389ea-9b82-4b98-ae47-18bb07062fd5\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200190_c-1.pdf\">2026062200190_c (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062200190_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-33b389ea-9b82-4b98-ae47-18bb07062fd5\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[136,926,4716],"class_list":["post-68716","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-antengene","tag-hkg-6996","tag-k2-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68716\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager\" \/>\n<meta property=\"og:description\" content=\"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68716\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T14:12:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T14:12:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager\",\"datePublished\":\"2026-06-22T14:12:30+00:00\",\"dateModified\":\"2026-06-22T14:12:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"HKG: 6996\",\"K2 Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68716#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68716\",\"name\":\"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-22T14:12:30+00:00\",\"dateModified\":\"2026-06-22T14:12:32+00:00\",\"description\":\"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68716\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68716#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68716","og_locale":"en_US","og_type":"article","og_title":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager","og_description":"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.","og_url":"https:\/\/flcube.com\/?p=68716","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T14:12:30+00:00","article_modified_time":"2026-06-22T14:12:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68716#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68716"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager","datePublished":"2026-06-22T14:12:30+00:00","dateModified":"2026-06-22T14:12:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68716"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","HKG: 6996","K2 Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68716#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68716","url":"https:\/\/flcube.com\/?p=68716","name":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-22T14:12:30+00:00","dateModified":"2026-06-22T14:12:32+00:00","description":"Antengene Corporation (HKG: 6996) announced a strategic global licensing agreement with US-based K2 Therapeutics for ATG-106, its first-in-class CDH6\u00d7CD3 bispecific T-cell engager (TCE) in preclinical development for solid tumors. The deal includes an additional option agreement for an undisclosed preclinical bispecific TCE candidate, with combined potential value exceeding US$980 million and global rights excluding Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68716#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68716"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68716#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene Corporation Secures $980M Global Licensing Deal with K2 Therapeutics for CDH6\u00d7CD3 Bispecific T-Cell Engager"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68716"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68716\/revisions"}],"predecessor-version":[{"id":68718,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68716\/revisions\/68718"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}